CANY
CGEM icon

Caxton Associates (New York)’s Cullinan Oncology CGEM Stock Holding History

Caxton Associates (New York)’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,541
Closed -$108K – 521
2023
Q1 		$108K Buy
+10,541
New +$116K 0.02% 461

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Caxton Associates (New York)'s CGEM Position: Q2 2023 in Review

Caxton Associates (New York) sold out of Cullinan Oncology (CGEM) in Q2 2023, closing a stake of 10,541 shares — an estimated $108K sold.

Caxton Associates (New York) first reported a position in CGEM in Q1 2023 and held it in 1 quarter. The position peaked at $108K in Q1 2023. 106 funds tracked by Wall St. Rank hold CGEM as of Q2 2023.

  • Caxton Associates (New York) reported no remaining Cullinan Oncology position as of Q2 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 10,541 Cullinan Oncology shares in Q2 2023, an estimated $108K.
  • Caxton Associates (New York) first reported a position in Cullinan Oncology in Q1 2023 and held it in 1 quarter.
  • Caxton Associates (New York)'s Cullinan Oncology position peaked at $108K in Q1 2023.
  • 106 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.